A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors

Phase 1/2 Active not recruiting 72 enrolled Tallac Therapeutics

NaSingle-groupOpen-labelTreatment

Summary

INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.

Timeline

Start: 2022-06-28
Primary completion: 2026-01-27
Completion: 2026-05-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TAC-001	Other / unclassified	—	Intravenous

Indications

No indication recorded.